M yocardial infarction (MI) is increasing worldwide and is a major cause of death in industrialized countries, with ≈25% of patients developing congestive heart failure (HF).
linking MR activation and its impact on MI is critical and may help to identify new biotargets in MI.
Lcn2 (lipocalin 2), also known in humans as NGAL (neutrophil gelatinase-associated lipocalin) or oncogene 24p3, was previously identified as a novel MR target in the cardiovascular system. [11] [12] [13] NGAL is a 25 kDa glycoprotein belonging to the lipocalin superfamily. 14, 15 In a recent study from our group, we demonstrated that NGAL plays a key role in blood pressure and cardiovascular extracellular matrix remodeling after MR activation. Genetic NGAL inactivation in mice blunted hypertension and vascular fibrosis induced by aldosterone/salt challenge. 12 We hypothesized that the MR target NGAL is a key factor in the development of cardiac fibrosis and cardiac dysfunction induced by MI, as MR activation is associated with deleterious effects in MI.
We studied the direct effects of NGAL on cardiac function and extracellular matrix remodeling by combining a clinical survey of NGAL serum levels in a cohort of post-MI patients and preclinical studies in NGAL knockout (KO) mice subjected to left coronary artery ligations. We explored underlying mechanisms in primary cultures of human cardiac fibroblasts, one of the major cellular components of the heart.
Methods
Detailed methods are available in the online-only Data Supplement.
Post-MI Cohort
The study population comprised 119 patients who were successfully reperfused after a first acute ST-segment-elevation myocardial infarction, included in a prospective monocentric cohort study (REMI Study [Relation Between Aldosterone and Cardiac Remodeling After Myocardial Infarction]), and performed in a university hospital between April 2010 and December 2013. 16 Patients underwent cardiac magnetic resonance during the first 4 days of the acute event and at the 6-month follow-up. The study was approved by an institutional review committee, and the subjects gave informed consent. It was sponsored by the Nancy Centre Hospitalier Régional Universitaire.
Myocardial Infarction
Experiments conformed to the 2010/63 directive of the European Union and the Guide for Care and Use of Laboratory Animals of the US National Institute of Health (No. 85-23). Left coronary artery ligations were performed in 8-week-old male NGAL KO C57BL/6J mice with MI (NGAL KO-MI; n=6-13) and wild-type littermates with MI (WT-MI; n=6-13) under anesthesia (3.6 mg/kg xylazine, intraperitoneal, plus 2% isoflurane). Analgesia was induced using buprenorphine (0.05 mg/kg, subcutaneous) just after induction of anesthesia and after 6, 12, 24, and 48 hours after coronary artery ligation. The snare was not tied for sham-operated mice (WT-Sham; n=6-9). Finerenone (1 mg/kg per day) was administered as a food additive for 7 days, starting the day after MI.
Cell Culture
Human cardiac fibroblasts were obtained from Promocell and maintained in medium (Fibroblast Media 3). Cells were cultured according to the manufacturer's instructions and used between passages 5 and 7. Cells were stimulated with aldosterone (10 −8 mol/L; Sigma), finerenone (10 −6 mol/L; Bayer), or recombinant human NGAL (hNGAL; 500 ng/mL; R&D Systems) for 24 hours for protein analysis. The doses were chosen based on previous studies. 6, 12 For the study of the intracellular pathways, cells were treated with recombinant hNGAL for 5, 10, 30, and 60 minutes. The chemical inhibitors PD98059 (Sigma Aldrich) and BAY 11-7082 (Sigma Aldrich) were added at 10 −5 mol/L 1 hour before NGAL stimulation.
Statistics
Data are presented as the means±SEM. Student t test (2-tailed) was used to compare paired groups of independent samples. ANOVA with Bonferroni adjustment for post hoc tests was used for multiple comparisons. Continuous data from the REMI cohort are presented either as the means+SD or the median (25-75 percentile) . A paired t test was used to compare values obtained at baseline and 6 months. The associations between baseline NGAL levels and changes in NGAL levels with LV ejection fraction (LVEF) recovery were evaluated using multivariable linear regression models. The outcome variable of this model was the change in the LVEF between baseline and 6 months, expressed as a continuous variable. Thus, a positive β value provided by the linear regression model indicates greater LVEF recovery (ie, an increased LVEF within 6 months of the baseline evaluation). Adjustment variables were selected a priori based on their known association with post-MI remodeling.
Data analysis was performed using GraphPad Prism V6.01 (GraphPad Software, San Diego, CA) Software Inc and SAS version 9.3 (SAS Institute Inc, Cary, NC). The predetermined significance level was P <0.05.
Results

NGAL Is Associated With Lower LVEF Recovery in Patients After MI
The study group consisted of 119 post-MI patients: 56±10 years old, 85.7% men, Killip class 2 to 3 9.2%, baseline median B-type natriuretic peptide 152 pg/mL (80-257), and loop diuretics at baseline 2.1%. Overall, NGAL levels remained stable during follow-up (71.6 ng/mL [60.3-91.3 ng/ mL] at baseline versus 71.7 ng/mL [55.9-89.0 ng/mL] at 6 months [P=0.35]), and the LVEF rose from 42±8% to 49±9% (P<0.001). In multivariable linear regression adjusted for anterior myocardial location, baseline B-type natriuretic peptide, baseline infarct size, and baseline LVEF, both higher baseline serum NGAL levels (β per 10 ng/mL increase=−0.82±0.25; P=0.001) and a larger increase in serum NGAL levels during follow-up (β per 10 ng/mL increase=−0.82±0.22; P=0.0003) were significantly associated with lower recovery of LVEF after 6 months, evaluated by cardiac magnetic imaging ( Table 1) .
Inactivation of NGAL Improves LV Function and Cardiac Remodeling in MI
We investigated the role of NGAL in the recovery of LV function and cardiac remodeling after MI in mice by inducing MI in NGAL KO mice and WT littermates. Of note, all functional and histological parameters were similar between WT-Sham and NGAL KO-Sham mice ( Table 1 in the online-only Data Supplement). We measured a 1.7-fold increase in cardiac NGAL protein levels at 7 days post-MI in WT mice ( Figure  S1 ) and aldosterone plasma levels in WT-MI mice (572.8±6.9 pg/mL) when compared with WT-Sham mice (416.7±6.9 pg/mL; P<0.05). Echocardiography showed that WT-MI mice at 7 days post-MI displayed greater LV end-systolic and end-diastolic diameters than sham-operated (WT-Sham) mice, together with reduced fractional shortening without modifications in stroke volume or in cardiac output. NGAL KO-MI mice partly blunted the modifications in LV diameters observed in WT-MI mice (Table 2) . Infarct size was similar between WT-MI and NGAL KO-MI (%: WT-MI 34±3, n=9 versus NGAL KO-MI 39±4, n=8; nonsignificant). December 2017
Echocardiography data 3 months post-MI showed that WT-MI mice displayed greater LV end-systolic and LV enddiastolic diameters than WT-Sham, together with reduced fractional shortening ( Table 2 ). This was accompanied by decreased stroke volume and reduced cardiac output in the WT-MI mice. NGAL KO-MI mice had a lower LV end-systolic diameter, with a trend toward better fractional shortening, than WT-MI mice, participating in the improvement of both stroke volume and cardiac output at 3 months post-MI (Table 2) .
Three months post-MI, LV hemodynamic studies showed that the dP/dt max and dP/dt min rates of LV pressure rise and fall, taken as indices of global LV contractility and diastolic function, were negatively altered in WT-MI versus WT-Sham mice, but were much less strongly affected in NGAL KO-MI mice ( Table 2) . LV pressure-volume curves showed that there were no modification of LV end-systolic pressure ( Figure 1A ) and no significant increase in LV end-diastolic pressure, that is, LV filling pressure, in the NGAL KO-MI mice relative to WT-Sham mice ( Figure 1B ). However, WT-MI mice had a lower LV end-systolic pressure-volume relation ( Figure 1A ) and higher LV end-diastolic pressure-volume relation than WT-Sham mice ( Figure 1B ), indicating impaired LV contractility and compliance, respectively. Again, both LV contractility and compliance were better in NGAL KO-MI than WT-MI mice ( Figure 1A and 1B).
Improvements in LV function were sustained by improvements in LV remodeling at 3 months post-MI: LV weight was higher for WT-MI than WT-Sham mice, whereas there was no increase in NGAL KO-MI mice (Table 2) . WT-MI mice presented and increase in myocyte cross-sectional area and the hypertrophic marker atrial natriuretic peptide ( Figure S2 ) when compared with WT-Sham mice, effects not prevented in NGAL KO mice. Furthermore, the increase in interstitial myocardial fibrosis observed in WT-MI mice was markedly reduced in NGAL KO-MI mice ( Figure 1C ). WT-MI mice presented an increase in cardiac α-SMA (α-smooth muscle actin) protein levels, an effect not observed in NGAL KO-MI mice ( Figure S3 ).
In addition, WT-MI mice showed an increase in several inflammatory markers such as IL-6 (interleukin-6; Figure S4A 
NGAL Mediates the Effects of Aldosterone in Human Cardiac Fibroblasts
We next investigated the role of NGAL in aldosteronemediated effects in human cardiac fibroblasts. Aldosterone induced NGAL protein synthesis in human cardiac fibroblasts ( Figure 2A ) and enhanced the secretion of collagen type I ( Figure 2B ) after 24 hours of stimulation. These effects were prevented by the MRA finerenone (Figure 2A and 2B) . Increased cardiac NGAL expression in MI was also blunted by finerenone treatment in vivo ( Figure S1 ). We studied the direct effect of NGAL on collagen production by treating human cardiac fibroblasts with recombinant hNGAL (500 ng/mL) for 24 hours. Human NGAL induced an increase in collagen type I ( Figure 2C ) and collagen type III ( Figure 2D ) protein levels. These data indicate that NGAL has direct profibrotic effects in human cardiac fibroblasts. Aldosterone also induced collagen type I ( Figure 2E ), but not collagen type III production in human cardiac fibroblasts ( Figure 2F ). We performed NGAL silencing experiments to investigate the role of NGAL in these aldosterone-mediated effects. siRNA-mediated downexpression of NGAL prevented the aldosterone-induced increase in collagen type I levels ( Figure 2E ). Altogether, these data suggest that NGAL may directly control collagen production in MI and that aldosterone/MR-mediated NGAL expression may be involved in the MR-mediated deleterious effects that are prevented by finerenone in MI. 10 
NFκB Mediates the Profibrotic Actions of NGAL
We then investigated the intracellular mechanism by which NGAL exerts its profibrotic effects in human cardiac fibroblasts. Recombinant hNGAL induced the phosphorylation of ERK 1/2 (extracellular signal-regulated kinases 1/2; Figure 3A ) and NFκB (nuclear factor-κB) after 5 minutes of stimulation ( Figure 3B ), whereas phosphorylation of STAT-3 (signal transducer and activator of transcription-3) was not altered ( Figure 3C ). The addition of PD98059, a specific inhibitor of ERK 1/2, was unable to block the hNGAL-mediated increase in collagen type I protein levels ( Figure 3D ). In contrast, pretreatment with BAY 11-7082, a specific NFκB pathway inhibitor, blocked the increase in collagen type I protein levels induced by hNGAL ( Figure 3E ), highlighting the role of NFκB in the profibrotic effect of NGAL. Our data indicate that NGAL could activate the NFκB pathway promoting an increase in the phosphorylation of its negative modulator IκB (inhibitor of nuclear factor-κB; Figure S5 ). BAY 11-7082 was also able to prevent the increase in collagen type I protein levels induced by aldosterone in human cardiac fibroblasts, indicating that NFκB activation has a key role in the profibrotic action of both aldosterone and NGAL in these cells ( Figure 3F ). Genetic deletion of NGAL in mice blunted the cardiac NFκB phosphorylation observed 7 days post-MI ( Figure 4A ), without modifications of NFκB phosphorylation in any of the groups studied at 3 months post-MI ( Figure S3 ).
Discussion
The purpose of this study was to investigate the role of the recently identified MR target NGAL in cardiac remodeling and function after MI. Serum NGAL was associated with less LVEF improvement after MI. We demonstrated that cardiac NGAL expression is elevated at 7 days post-MI and that this effect is dependent on MR activation. The absence of NGAL expression in vivo prevented the interstitial cardiac fibrosis, inflammation, and cardiac dysfunction observed after MI. Recombinant human NGAL exerted direct profibrotic actions in human cardiac fibroblasts by increasing collagen type I, whereas NGAL knockdown prevented aldosterone-induced synthesis of collagen type I. The MR target NGAL thus seems to be a key mediator of cardiac damage induced by MI, through its profibrotic properties.
Increased systemic levels of NGAL have been reported in clinical studies in patients with MI. [17] [18] [19] [20] NGAL is also a biomarker of renal injury, 21, 22 and it is thus difficult to dissociate the modulation of NGAL, related to renal dysfunction, associated with cardiovascular diseases from a direct relationship with cardiac or vascular injury. NGAL plasma levels are elevated in coronary heart disease in patients without renal dysfunction 23 and correlate with the severity of the disease. 19 In addition, NGAL predicts mortality and cardiovascular disease in older adults without kidney disease, 24 as well as in patients with HF after MI. 25, 26 In the present study, increased serum NGAL levels were correlated with lower LVEF recovery in post-MI patients after 6 months. NGAL has already been reported to be associated with clinical outcome in a biomarker substudy of the OPTIMAAL trial (Optimal Trial in Mydocardial infarction With the Angiotensin II Antagonist Losartan). 26 Patients in the REMI cohort were of similar age (55 years old) but had higher LVEF (50% versus 32%) when compared with the OPTIMAAL biomarker substudy population. Most importantly, all patients included in the OPTIMAAL substudy were NYHA 2 (New York Heart Association) or higher, whereas only 3 patients of the REMI population had diuretics, suggesting that the vast majority had no symptoms of HF. In the REMI cohort, our results indicate that higher serum NGAL is associated with less LVEF improvement (ie, less reverse remodeling) after MI. Reverse remodeling has been mainly studied after cardiac resynchronization 27 but is also frequent after MI. It has been reported to occur in a third of patients after MI and is strongly associated with favorable clinical outcome. 28, 29 Of note, Funaro et al 28 reported that in a cohort of acute MI, the only variable (while competing with age and baseline systolic LV volumes) significantly associated with a 2-year event-free survival was reverse remodeling (hazard ratio, 0.28 [0.12-0.66]). Similarly, Spinelli et al 29 reported extreme association (HR, <0.20) between reverse remodeling and the composite of reinfarction, HF hospitalization and death. As a consequence, our results, in light of the aforementioned evidence, suggest that higher NGAL levels could have a detrimental effect in patients after MI through its association with less reverse ischemic remodeling. A limitation of the analysis deserves to be mentioned. Because the REMI cohort was primarily design to study the factors associated with the early myocardial remodeling post-MI, no control population was considered.
Elevated vascular and myocardial levels of NGAL have been reported in several experimental models of cardiovascular diseases, such as atherosclerosis 30 and aortic abdominal aneurysm, 31 as well as after MI. 26, [32] [33] [34] We confirmed these results in mice at 7 days post-MI and showed that increased NGAL levels were because of MR activation. A previous study showed that the lack of NGAL improved the functional recovery and reduced infarct size of isolated mouse hearts subjected to ischemia/reperfusion. This effect was associated with the restoration of mitochondrial function and phospholipid remodeling. 35 Mice lacking NGAL were protected from cardiac cell death and elicited a higher autophagic response in a study limited to the first 24 hours after cardiac ischemia. 33 We show in the present study that the absence of NGAL expression in vivo is beneficial after MI, reducing cardiac fibrosis, inflammation, and the impairment of cardiac function.
Changes in collagen synthesis occur in patients with congestive HF and LV systolic dysfunction after acute MI, 1 an effect partially mediated by MR activation. 10 Finerenone is a highly selective nonsteroidal MRA that mediates end-organ protection with a lower risk of electrolyte disturbances than other MRAs. 36 Previous studies have demonstrated the beneficial effects of finerenone, which improves post-MI LV function. 10, 36 We show here that NGAL levels did not increase at 7 days post-MI in finerenone-treated animals and that aldosterone modulates NGAL expression through MR activation in human cardiac fibroblasts. Indeed, aldosterone also modulates NGAL expression in cardiomyocytes and smooth muscle cells. 11 We further demonstrated that NGAL mediates the profibrotic actions of aldosterone in human cardiac fibroblasts: aldosterone did not increase collagen type I protein levels in NGAL knockdown cells. We propose that NGAL is a mediator of aldosteroneinduced fibrosis after MI. This is in accordance with another experimental setting where we reported that genetic disruption of NGAL prevented hypertension and cardiovascular remodeling associated with MR activation by aldosterone treatment. 12 The underlying mechanisms linking NGAL, MR activation, and collagen type I expression are centered on NFκB activation; we demonstrated that NFκB activation is necessary for the profibrotic effects of NGAL. NFκB regulates many processes in the cardiovascular system, including inflammation, cell survival, differentiation, fibrosis, and proliferation. 37 NFκB is a key regulator of cardiac responses to ischemia and reperfusion. The alterations in oxygen availability that occur in MI can activate NFκB. 38 Several studies have demonstrated that NFκB is upregulated 3 days after MI in mice 39 and that this increase is maintained at 7 and 30 days post-MI. [40] [41] [42] These results are in accordance with our data showing an increase in the phosphorylation of NFκB 7 days after MI. Frantz et al 43 have demonstrated that the genetic inactivation of NFκB improves survival and reduces LV dilatation 8 weeks after MI. Our data suggest that NGAL could activate NFκB through a phosphorylation of IκB. In addition, inhibition of NFκB phosphorylation by pharmacological approaches reduced extracellular matrix deposition and adverse cardiac remodeling after MI. 40, 41 NFκB is therefore involved in the NGAL-mediated profibrotic effect of aldosterone, as summarized in Figure 4B .
In conclusion, this study demonstrates the beneficial effects of NGAL deletion in mice subjected to left artery coronary ligation by limiting cardiac fibrosis, inflammation, and LV dysfunction associated with MI. It also demonstrates the detrimental effect of increased cardiac NGAL levels within days of MI and shows a correlation between circulating NGAL levels and reduced recovery of systolic function in patients during the first 6 months after an MI. NGAL is a novel mediator of the actions of aldosterone and is an exciting potential therapeutic target for cardiovascular diseases in which MR is involved, such as MI, as well as perhaps mineralocorticoid-independent extracellular matrix remodeling in the cardiovascular system and beyond.
Perspectives
NGAL, which is overexpressed by the heart after MI, is an emerging potential therapeutic target for the detrimental consequences associated with MI. NGAL deletion blocks cardiac dysfunction and fibrosis in experimental MI. Further studies are required to establish the potential therapeutic benefit of NGAL inhibition in patients with MI. 
